Video
Considerations For ADT Selection And Patient Education on Treatment-Related AEs
Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.
Video Player is loading.
January 2023 AbbVie Inc. Company Confidential
Related Videos
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Related Content
